» Articles » PMID: 17726594

[Gastrointestinal Involvement in Systemic Sclerosis. An Underestimated Complication]

Overview
Journal Hautarzt
Specialty Dermatology
Date 2007 Aug 30
PMID 17726594
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic sclerosis (SSc) belongs to the family of autoimmune connective tissue diseases and is still a challenge to every practicing physician. The disorder is characterized by progressing fibrosis of the skin and internal organs, abnormal activation of the immune system, and distinct changes in microcirculation. Although it is rare--with a prevalence of about 20:100000--patients need to be cared for in a daily setting. In general thickening of the skin is the first sign of the disease, so dermatologists are most frequently consulted first. Two subtypes exist, limited and diffuse forms. Both entities usually involve internal organs, and therefore interdisciplinary cooperation is mandatory. The increased morbidity and mortality depend predominantly on the grade of involvement of the affected organs. Therefore it is essential to diagnose systemic sclerosis early and to identify and monitor all complications closely. In this respect gastrointestinal involvement is frequently neglected, owing to its primarily non-life-threatening character, resulting in substantially delayed therapy.

Citing Articles

[The German network for systemic sclerosis (DNSS): current data on diagnostics and therapy].

Hunzelmann N, Krieg T Hautarzt. 2012; 63 Suppl 1:71-5.

PMID: 22543950 DOI: 10.1007/s00105-011-2300-0.


Profile of gastrointestinal involvement in patients with systemic sclerosis.

Schmeiser T, Saar P, Jin D, Noethe M, Muller A, Soydan N Rheumatol Int. 2011; 32(8):2471-8.

PMID: 21769490 DOI: 10.1007/s00296-011-1988-6.


[Systemic sclerosis].

Muller-Ladner U Internist (Berl). 2008; 49(3):278-85.

PMID: 18210018 DOI: 10.1007/s00108-007-2011-x.

References
1.
Sallam H, McNearney T, Chen J . Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006; 23(6):691-712. DOI: 10.1111/j.1365-2036.2006.02804.x. View

2.
Bortolotti M, Turba E, Tosti A, Sarti P, Brunelli F, Del Campo L . Gastric emptying and interdigestive antroduodenal motility in patients with esophageal scleroderma. Am J Gastroenterol. 1991; 86(6):743-7. View

3.
Sjolund K, Bartosik I, Lindberg G, Scheja A, Wildt M, Akesson A . Small intestinal manometry in patients with systemic sclerosis. Eur J Gastroenterol Hepatol. 2005; 17(11):1205-12. DOI: 10.1097/00042737-200511000-00009. View

4.
SJOGREN R . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994; 37(9):1265-82. DOI: 10.1002/art.1780370902. View

5.
Caserta L, de Magistris L, Secondulfo M, Caravelli G, Riegler G, Cuomo G . Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol Int. 2003; 23(5):226-30. DOI: 10.1007/s00296-003-0286-3. View